ANGPT1, angiopoietin 1, 284

N. diseases: 340; N. variants: 18
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE In POP<sup>-/-</sup> mice, the increase in Ang-(1-7) was also blunted as compared with WT mice (309±46 and 472±28 fmol/mL, respectively <i>P</i>=0.01), and moreover, the rate of recovery from acute Ang II-induced hypertension was delayed (<i>P</i>=0.016). 31786979 2020
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE Monocyte miR-27a in EVs decreases Mas receptor expression and eNOS phosphorylation in endothelium, impairs Ang-(1-7)-mediated vasodilation and causes hypertension. 31328772 2020
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE The differential MasR trafficking in neurons from SHRs may contribute to the impaired responses of Ang-(1-7) and to hypertension development. 31825460 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 GeneticVariation group BEFREE Hypertension was induced in adult Sprague-Dawley rats by infusion of aldosterone (ALDO; 0.75 μg/hour) for 4 weeks with or without co-treatment of Ang1-7 (1 mg/kg/day).Untreated rats served as controls. 30715105 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE This study was designed to determine whether inhibition of Ang-(1-7) in the hypothalamic paraventricular nucleus (PVN) attenuates sympathetic activity and elevates blood pressure by modulating pro-inflammatory cytokines (PICs) and oxidative stress in the PVN in salt-induced hypertension. 30328008 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE These data show that treatment with DIZE or Ang-(1-7) during gestation promoted beneficial effects of attenuating hypertension and cardiac remodeling in adult offspring. 31506648 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE Although further studies are required to determine whether Mito-TEMPO or CAN + Ang-(1-7) treatment at the doses used altered mitochondrial ROS, optimal therapeutic benefits are achieved by shifting the balance from Ang II toward Ang-(1-7) in this model of chronic RAS-dependent hypertension. 30540685 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE In this study, we have evaluated ACE-inhibitory potential of the tripeptide l-Phenylalanyl-d-Histidyl-l-Leucine (l-Phe-d-His-l-Leu) in vitro and its antihypertensive effect in rat model of dexamethasone-induced hypertension. l-Phe-d-His-l-Leu was custom-designed by changing the configuration of penultimate amino acid residue (histidine) from C-terminal of Ang I, the site at which ACE acts upon and generates Ang II. l-Phe-d-His-l-Leu effectively inhibited ACE activity in a dose-dependent and competitive manner with an IC<sub>50</sub> of 53.32 ± 0.13 nmol/L. 30481537 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE While the beneficial effects of Ang-(1-7) have been widely studied in several experimental models of hypertension, much less studies were performed in experimental models of atherosclerosis. 29541937 2018
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE The protective effects of Ang-(1-9) against pulmonary hypertension were inhibited by Ang type 2 receptor (AT<sub>2</sub>R) blocker, but not by Mas receptor blocker. 29962859 2018
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE Large body of experimental data confirmed sustained beneficial effects of ACE2/Ang-(1-7)/Mas receptor axis activation on hypertension and vascular injury. 27889958 2017
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE The present review examined recent findings regarding the physiological and biological roles of the ACE2‑Ang‑(1‑7)‑Mas axis in the cardiovascular system, discussed potential food‑derived ACE2‑activating agents, and highlighted initiatives, based on this axis, that aim to develop functional foods for the treatment of hypertension. 28791402 2017
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE Ang(1-7) might therefore represent a promising therapy for obstructive sleep apnea-related hypertension and renal injury. 28076452 2017
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 GeneticVariation group BEFREE These alterations indicate an imbalance in the urinary RAAS, promoting the actions of Ang II at the expense of Ang-(1-7), which over time may increase the risk of renal inflammation and fibrosis and ultimately hypertension and renal disease. 27636897 2017
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE Ang 1-7 infusion increased blood pressure, cardiac interstitial fibrosis and cardiac ACE binding compared to untreated STNx rats. 28192475 2017
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 GeneticVariation group BEFREE The circulating ACE2 and Ang-(1-7) levels were related to neither rs4646155 nor rs879922 in female or male patients.In conclusion, the rs2106809 polymorphism of the ACE2 gene may be a determinant of the circulating Ang-(1-7) level in female patients with hypertension, suggesting a genetic association between circulating Ang-(1-7) levels and ACE2 gene polymorphisms in patients with hypertension. 27310975 2016
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE Although previous studies have demonstrated that Ang-1 might play an important role in the development of familial pulmonary hypertension, the role of Ang-1 in the development of the pulmonary hypertension associated with CDH is poorly understood. 22917924 2013
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE Differential regulation of signaling pathways in aging and hypertension by Ang II versus Ang-(1-7) may contribute to the autonomic dysfunction accompanying these states. 21367658 2011
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 AlteredExpression group BEFREE This prevention of hypertension by ACE2 overexpression was reversed by blockade of the Ang-(1-7) receptor (d-Ala7-Ang-[1-7]; 600 ng/kg per minute). 19926873 2010
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE Here we examined whether soluble human recombinant ACE2 (rACE2) can efficiently lower Ang II and increase Ang-(1-7) and whether rACE2 can prevent hypertension caused by Ang II infusion as a result of systemic versus local mechanisms of ACE2 activity amplification. rACE2 was infused via osmotic minipumps for 3 days in conscious mice or acutely in anesthetized mice. rACE2 caused a dose-dependent increase in serum ACE2 activity but had no effect on kidney or cardiac ACE2 activity. 19948988 2010
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE Rodents engineered to express angiopoietin 1 (Ang-1) constitutively in the lung develop severe pulmonary hypertension. 14512515 2003
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 Biomarker group BEFREE A mechanistic link between familial and acquired pulmonary hypertension was demonstrated by the finding that angiopoietin-1 shuts off the expression of BMPR1A, a transmembrane protein required for BMPR2 signaling, in pulmonary arteriolar endothelial cells. 12571257 2003
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease
0.100 AlteredExpression group BEFREE We hypothesized that aberrant expression of the angiopoietin-1 gene in the adult lung would be a major contributing factor in the development of pulmonary hypertension. 11436038 2001